Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Update

Assembly Biosciences, Inc. (NASDAQ:ASMB) saw a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 15,900 shares, an increase of 37.1% from the November 15th total of 11,600 shares. Based on an average daily volume of 33,200 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.4% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. HC Wainwright restated a “neutral” rating on shares of Assembly Biosciences in a research report on Tuesday, September 24th. Jefferies Financial Group raised Assembly Biosciences from a “hold” rating to a “buy” rating and upped their price objective for the stock from $2.00 to $35.00 in a research note on Friday, September 20th.

Assembly Biosciences Stock Up 0.2 %

Shares of ASMB traded up $0.03 during midday trading on Friday, hitting $15.38. 10,278 shares of the company traded hands, compared to its average volume of 33,699. The firm has a 50 day moving average of $16.43 and a 200-day moving average of $15.60. Assembly Biosciences has a 52 week low of $8.82 and a 52 week high of $19.93.

Insider Buying and Selling

In other news, major shareholder Alexander Schornstein bought 10,000 shares of the firm’s stock in a transaction on Tuesday, October 8th. The shares were bought at an average price of $14.58 per share, for a total transaction of $145,800.00. Following the purchase, the insider now owns 703,113 shares in the company, valued at approximately $10,251,387.54. The trade was a 1.44 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders have sold 394 shares of company stock valued at $5,894. 5.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Assembly Biosciences

Hedge funds have recently made changes to their positions in the company. Armistice Capital LLC purchased a new position in shares of Assembly Biosciences in the 2nd quarter worth $6,421,000. Renaissance Technologies LLC lifted its holdings in shares of Assembly Biosciences by 39.2% in the 2nd quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company’s stock valued at $753,000 after acquiring an additional 15,451 shares during the last quarter. FMR LLC grew its position in Assembly Biosciences by 29.7% in the third quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock worth $240,000 after acquiring an additional 3,635 shares in the last quarter. Finally, Acadian Asset Management LLC increased its stake in Assembly Biosciences by 131.0% during the second quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company’s stock worth $184,000 after acquiring an additional 7,690 shares during the last quarter. 19.92% of the stock is currently owned by hedge funds and other institutional investors.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.